New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes

Core Insights - Castle Biosciences, Inc. is presenting research at the 2025 ASCO Annual Meeting that highlights the effectiveness of the DecisionDx-Melanoma test in reducing mortality risk for melanoma patients by 32% compared to untested patients [1][2][3] Group 1: DecisionDx-Melanoma Test - The DecisionDx-Melanoma test is a 31-gene expression profile that provides independent risk stratification for cutaneous melanoma patients, demonstrating significant mortality risk predictions [2][4] - In a study involving over 13,500 patients, the DecisionDx-Melanoma test showed a Class 2B hazard ratio of 4.59 and a Class 1B/2A hazard ratio of 3.42, indicating its strong predictive capability for melanoma-specific mortality [2][3] - The test has been ordered more than 200,000 times for patients diagnosed with cutaneous melanoma, supporting its clinical value through over 50 peer-reviewed studies [4][6] Group 2: DecisionDx-UM Test - The DecisionDx-UM test is a 15-gene expression profile that predicts the risk of metastasis in uveal melanoma patients and is widely used in ocular oncology practices in the U.S. [5] - The test is recognized in AJCC staging and NCCN guidelines as a prognostic factor, with nearly 80% of uveal melanoma patients in the U.S. receiving it as part of their diagnostic workup [5][6] Group 3: Research and Development - Castle Biosciences is actively engaged in research and development for tests addressing high clinical needs, including a test for guiding systemic therapy selection for atopic dermatitis [7] - The company aims to transform disease management through innovative tests that prioritize patient care [6][7]